Anti-CLEC12A / CD371 Reference Antibody (tepoditamab)
Recombinant Antibody
- 产品详情
- 实验流程
Application ![]()
| FC, Kinetics, Animal Model |
---|---|
Primary Accession | Q5QGZ9 |
Reactivity | Human |
Clonality | Monoclonal |
Isotype | IgG1 |
Calculated MW | 30762 Da |
Target/Specificity | CLEC12A / CD371 |
---|---|
Endotoxin | < 0.001EU/ µg,determined by LAL method. |
Conjugation | Unconjugated |
Expression system | CHO Cell |
Format | Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column. |
Name | CLEC12A {ECO:0000303|PubMed:16838277, ECO:0000312|HGNC:HGNC:31713} |
---|---|
Function | Myeloid inhibitory C-type lectin receptor that acts as a negative regulator of myeloid cell activation (PubMed:14739280, PubMed:15238421, PubMed:16239426, PubMed:34234773, PubMed:38367667, PubMed:38386511, PubMed:39143217). Myeloid cell inhibition is required to limit proinflammatory pathways and protect against excessive inflammation (By similarity). Specifically recognizes and binds various structures, such as neutrophil extracellular traps (NETs) or monosodium urate crystals (PubMed:38367667, PubMed:38386511, PubMed:39143217). Also acts as a pattern-recognition receptor for pathogen-associated molecules, such as plasmodium hemozoin or mycobacterial micolic acid (PubMed:31269448, PubMed:36542980). Ligand-binding induces phosphorylation of its ITIM motif, followed by recruitment of tyrosine- protein phosphatases PTPN6 and PTPN11, which counteract tyrosine- protein kinase SYK, thereby preventing myeloid cell activation (PubMed:14739280, PubMed:16239426, PubMed:34234773). Acts as a pattern- recognition receptor for NETs in neutrophils: specifically recognizes DNA in NETs, leading to inhibit neutrophil activation and limit further NET formation (PubMed:39143217). This regulation is essential for controlling key neutrophil responses and limit NET-mediated inflammatory conditions (By similarity). Also recognizes dead cells by acting as a receptor for monosodium urate crystals, leading to down- regulate neutrophil activation (PubMed:38367667, PubMed:38386511). Binding to monosodium urate crystals also promotes the type I interferon response (By similarity). Acts as an inhibitor of natural killer (NK) cell cytotoxicity (PubMed:15238421). Also acts as an ihibitor of dendritic cell maturation in an IL10-dependent manner (PubMed:16239426). |
Cellular Location | Cell membrane; Single-pass type II membrane protein. Note=Ligand binding leads to internalization (PubMed:16239426). Clusters at phagocytic vesicles upon monosodium urate crystal-binding (PubMed:38367667) |
Tissue Location | Preferentially expressed in lymphoid tissues and immune cells, including natural killer (NK) cells, T-cells, dendritic cells and monocytes or macrophages (PubMed:14739280, PubMed:15238421, PubMed:15548716, PubMed:16239426, PubMed:16838277). Detected in spleen macrophage-rich red pulp and in lymph node (at protein level) (PubMed:16838277). Detected in peripheral blood leukocytes, dendritic cells, bone marrow, monocytes, mononuclear leukocytes and macrophages (PubMed:16838277). |
Research Areas
For Research Use Only. Not For Use In Diagnostic Procedures.
Application Protocols
Provided below are standard protocols that you may find useful for product applications.

终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
¥ 1,500.00
Cat# APR10444